Medicus Pharma Reports Q3 2026 Financial Results and Strategic Shift Toward Precision Oncology
Medicus Pharma (MDCX) reported a net loss of $35.9 million for the first nine months ended September 30, 2026, an increase from $27.3 million in the prior-year period. The company's third-quarter net loss was $15.2 million. Operating expenses reached $34.5 million, driven largely by a $10 million research and development charge related to the CD228V asset and costs associated with an organizational transformation. The company is pursuing several strategic initiatives, including a proposed business combination for SkinJect with a nonbinding enterprise valuation of $135 million. Additionally, Medicus is focusing on its precision oncology pipeline, specifically targeting a 30% or higher objective response rate in melanoma for the CD228V asset. While the company raised $36.2 million in financing during the first nine months, total liabilities rose to $25 million due to new debt obligations.
Topics: cash balance financial results net loss operating expenses research and development
Read the full article at Motley Fool
Part of the story Bakkt Reports Q3 2026 Financial Results Amid Strategic Shift to Stablecoin Infrastructure (5 articles)